SEMIQUANTITATIVE EVALUATION OF 99MTCTRODAT1 BINDING POTENTIAL BY TWO METHODS OF SPECT IMAGE RECONSTRUCTION.
DOI:
https://doi.org/10.15392/bjrs.v7i2A.638Keywords:
SPECT, TRODAT-1, OSEM, , Filtered Back Projection, Dopamine TransporterAbstract
TRODAT-1 is a radiopharmaceutical derived from tropane and linked to tecnecium-99m ([99mTc] TRODAT-1) has been used in studies of dopamine transporter (DAT) in central nervous system. Associated with the SPECT technique of acquisition, is able to detect changes in neurological disorders like Parkinson´s disease, evaluating the binding potential (BP) of DAT. The aim of this study was to evaluate the influence of the image reconstruction methods, Filtered Back Projection (FBP) and iterative reconstruction (OSEM), in BP values at the striatal region in 30 healthy volunteers. Images were analyzed by visual inspection and semi-quantitative analysis. Regions of interest (ROI) were made over striatal areas on both sides. Nonparametric Wilcoxon statistical analysis was performed between the BP values from the FBP and OSEM methods. Our results showed that the reconstruction methods have a statistical significant BP values difference in the total striatum (Z = -2,2787 p = 0.005), right striatum (Z = -2,602 p = 0.009) and left striatum (Z= 2,746 p = 0.006). The effect size was calculated to see if there influence in this test: the "large effect size" for all measurements was observed (total striatum r= -0.51; right striatum r= -0.48; left striatum r= -0.50). FBP is the usual method of reconstruction for brain SPECT images, and our results showed influence of the OSEM method in BP. It is concluded that the method of image reconstruction adopted should be standardized to avoid incorrect evaluations of BP values using [99mTc]TRODAT-1.
Downloads
References
Mozley LH, Gur RC, Mozley PD, Gur RE. “Striatal dopamine transporters and cognitive functioning in healthy men and women”. Am J Psychiatry. 158:1492–9 (2001).
Nieoullon A, Coquerel A. “Dopamine: a key regulator to adapt action, emotion, motivation and cognition”. Curr Opin Neurol. 16 (Suppl 2):S3–9 (2003).
Reith E, Xu C, Chen NH. “Pharmacology and regulation of the neuronal dopamina transporter”. Eur J Pharmacol. 324:1–10 (1997).
Jaber M, Jones S, Giros B, Caron MG. “The dopamine transporter: a crucial component regulating dopamine transmission”. Mov Disord. 12:629–33 (1997).
Gelb DJ, Oliver E, Gilman S. “Diagnostic criteria for Parkinson disease”. Arch Neurol. 56(1):33-9 (1999).
Tanner CM, Goldman SM. “Epidemiology of Parkinson’s disease”. Neurol Clin. 1996;14(2):317-35.
Hughes AJ, Daniel SE, Kilford L, Lees AJ. “Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinicopathological study of 100 cases”. J Neurol Neurosurg Psychiatry. 55(3):181-4 (1992).
Shih MC, Hoexter MQ, Andrade LAF, Bressan RA. “Parkinson’s disease and dopamine transporter neuroimaging – a critical review”. Sao Paulo Med J. 2006;124(3):168-75.
Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS. “Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study”. J Clin Psychopharmacol. 23(1):5-14 (2003).
Acton PD, Kushner SA, Kung MP, Mozley PD, Plossl K, Kung HF. “Simplified reference region model for the kinetic analysis of [99mTc]TRODAT-1 binding to dopamine transporters in nonhuman primates using single- photon emission tomography”. Eur J Nucl Med. 26(5):518-26 (1999).
Meegalla SK, Plossl K, Kung MP, et al. “Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter—imaging agents”. J Med Chem. 40:9–17 (1997).
Harvey A. Ziessman & James H. Thrall. Medicina Nuclear. Elsevier & Brasil (2014).
Koch W, Suessmair C, Tatsch K, Pöpperl G. “Iterative reconstruction or filtered backprojection for semi-quantitative assessment of dopamine D2 receptor SPECT studies?”. Euro Jour Nucl Med Mol Imag. 38(6):1095-1103 (2011).
Shih MC, Amaro Jr E, Ferraz HB, et al. “Neuroimaging of the Dopamine Transporter in Parkinson´s Disease – First study using [99mTc]-TRODAT-1 and SPECT in Brazil”. Arq Neuropsiquiatr. 64(3-A):628-634 (2006).
Barsottini OGP, Felício AC, Aguiar PC, Godeiro-Junior C, Shih MC, Hoexter MQ, Bressan RA, Ferraz HB, Andrade LAF. “Clinical and molecular neuroimaging characteristics of Brazilian patients with Parkinson’s disease and mutations in PARK2 or PARK8 genes”. Arq Neuropsiquiatr. 67(1):7-11 (2009).
Shih MC, Andrade LAF, Amaro-Jr E, Felício AC, Ferraz HB, et al. “Higher nigroestriatal dopamine neuron loss in early than late onset Parkinson´s disease? A [99mTc]-TRODAT-1 SPECT study”. Mov. Disord. (22):863-866 (2007).
Felício AC, Godeiro-Junior C, Moriyama TS, Shih MC, et. al. “Degenerative parkinsonism in patients whit psychogenic parkinsonism: A dopamine transporter imaging study”. Clin. Neurol. & Neurosurg. 112(4): 282-285(2010).
Felício AC, Moriyama TS, Godeiro-Junior C, Shih MC, Hoexter MQ, Borges V, Silva SM, Amaro-Junior E, Andrade LA, Ferraz HB, Bressan RA. “Higher dopamine transporter density in Parkinson's disease patients with depression”. Psychopharmacology (Berl). 211(1):27-31 (2010).
Felício AC, Godeiro-Junior C, Shih MC, Borges V, Silva SM, Aguiar Pde C, Hoexter MQ, Barsottini OG, Andrade LA, Bressan RA, Ferraz HB. “Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1”. J Neurol Sci. 291(1-2):64-8 (2010).
Published
Issue
Section
License
Copyright (c) 2021 Brazilian Journal of Radiation Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/